Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Absci Corporation is a pre-revenue AI-powered drug discovery platform company that uses proprietary generative AI and synthetic biology to design and optimize antibody therapeutics for pharmaceutical partners. The company operates a fee-for-service model with pharmaceutical collaborators while building an internal pipeline of wholly-owned drug candidates, positioning itself at the intersection of computational biology and therapeutic development. With a $400M market cap and negative cash flow of $100M annually, Absci is a high-risk, early-stage biotech dependent on partnership economics and clinical validation.
Absci generates revenue through multi-year collaboration agreements where pharma partners pay upfront fees, research funding, and potential milestone payments to access its AI-driven Integrated Drug Creation platform for designing novel antibody therapeutics. The platform combines generative AI models trained on proprietary datasets with wet-lab validation using E. coli-based expression systems to accelerate antibody discovery and optimization. Pricing power is currently limited as the company competes with established CROs and emerging AI-bio platforms, requiring proof of clinical success to command premium economics. The company is transitioning toward a hybrid model with wholly-owned pipeline assets (including oncology programs) that could generate future royalties, but this requires substantial capital investment with 5-10 year timelines to potential commercialization.
Announcements of new pharmaceutical partnerships or expansion of existing collaborations with upfront payments
Clinical trial data readouts or IND filings for wholly-owned pipeline candidates (particularly oncology programs)
Validation publications or presentations demonstrating AI platform superiority in antibody design metrics (affinity, developability, speed)
Cash runway updates and financing events given $100M annual burn rate against current market cap
Competitive developments in AI-driven drug discovery space (partnerships by Absci competitors, M&A activity)
Unproven clinical translation of AI-designed antibodies - no Absci-originated therapeutic has reached late-stage trials, creating platform validation risk that could render the technology commercially unviable
Rapid commoditization of AI drug discovery as large pharma builds internal capabilities and competitors (Recursion, Schrodinger, Relay) scale similar platforms, potentially eroding partnership economics
Regulatory uncertainty around AI-designed biologics and potential FDA requirements for additional validation studies that could negate speed advantages
Competition from established CROs (Charles River, WuXi) with broader service offerings and validated track records, plus emerging AI-bio platforms (Absci, Recursion, Insitro) competing for same pharma partnerships
Risk of pharmaceutical partners developing internal AI capabilities and reducing reliance on external platforms, particularly as foundational AI models become more accessible
Inability to differentiate platform capabilities in head-to-head comparisons, forcing price-based competition that undermines unit economics
Severe cash burn of $100M annually against $400M market cap creates imminent financing risk - likely needs capital raise within 12-18 months at current burn rate, risking substantial dilution at depressed valuation
Declining revenue (-20.7% YoY) while maintaining high fixed costs suggests deteriorating partnership traction, potentially forcing down-round financing or strategic sale
No clear path to profitability without either substantial partnership expansion or clinical success of proprietary pipeline, both multi-year uncertain outcomes
moderate - While drug discovery spending by large pharma is relatively recession-resistant, biotech funding cycles are highly sensitive to risk appetite and growth stock valuations. Economic downturns reduce venture capital availability for follow-on financings and compress biotech valuations, creating existential risk for pre-revenue companies. However, pharmaceutical R&D budgets (Absci's customer base) tend to be more stable through cycles as large-cap pharma maintains strategic innovation priorities.
High sensitivity to interest rates through multiple channels: (1) As a pre-revenue growth company, Absci's valuation is based on discounted future cash flows 5-10+ years out, making it extremely sensitive to discount rate changes - rising rates compress NPV of distant milestones; (2) Higher rates reduce risk appetite for speculative biotech, contracting sector multiples; (3) Financing costs increase for future capital raises, though current debt is minimal (0.03 D/E). The 10-year Treasury yield directly impacts comparable biotech valuations and investor willingness to fund cash-burning platforms.
Minimal direct credit exposure given negligible debt (3% debt-to-equity) and strong current ratio (5.89x), but significant indirect exposure through biotech financing markets. Widening credit spreads signal risk-off sentiment that reduces availability of growth capital for pre-revenue biotechs, potentially forcing dilutive financings or strategic pivots. The company's survival depends on access to equity capital markets rather than credit markets.
growth - Attracts highly speculative, venture-style public market investors willing to accept binary outcomes and multi-year timelines for platform validation. The stock appeals to thematic AI/biotech crossover investors betting on computational biology disruption, but requires high risk tolerance given pre-revenue status, cash burn, and lack of clinical proof points. Not suitable for value or income investors given negative margins and no path to near-term profitability.
high - Extreme volatility typical of pre-revenue biotech with binary catalysts. The 54% one-year decline and small $400M market cap create susceptibility to large percentage moves on partnership news, financing events, or sector rotation. Stock likely exhibits beta >2.0 relative to biotech indices, amplifying both sector rallies and selloffs. Low institutional ownership and limited analyst coverage further reduce liquidity and increase volatility.
